Literature DB >> 20020375

Androgenic anabolic steroid abuse and the cardiovascular system.

Paul Vanberg1, Dan Atar.   

Abstract

Abuse of anabolic androgenic steroids (AAS) has been linked to a variety of different cardiovascular side effects. In case reports, acute myocardial infarction is the most common event presented, but other adverse cardiovascular effects such as left ventricular hypertrophy, reduced left ventricular function, arterial thrombosis, pulmonary embolism and several cases of sudden cardiac death have also been reported. However, to date there are no prospective, randomized, interventional studies on the long-term cardiovascular effects of abuse of AAS. In this review we have studied the relevant literature regarding several risk factors for cardiovascular disease where the effects of AAS have been scrutinized:(1) Echocardiographic studies show that supraphysiologic doses of AAS lead to both morphologic and functional changes of the heart. These include a tendency to produce myocardial hypertrophy (Fig. 3), a possible increase of heart chamber diameters, unequivocal alterations of diastolic function and ventricular relaxation, and most likely a subclinically compromised left ventricular contractile function. (2) AAS induce a mild, but transient increase of blood pressure. However, the clinical significance of this effect remains modest. (3) Furthermore, AAS confer an enhanced pro-thrombotic state, most prominently through an activation of platelet aggregability. The concomitant effects on the humoral coagulation cascade are more complex and include activation of both pro-coagulatory and fibrinolytic pathways. (4) Users of AAS often demonstrate unfavorable measurements of vascular reactivity involving endothelial-dependent or endothelial-independent vasodilatation. A degree of reversibility seems to be consistent, though. (5) There is a comprehensive body of evidence documenting that AAS induce various alterations of lipid metabolism. The most prominent changes are concomitant elevations of LDL and decreases of HDL, effects that increase the risk of coronary artery disease. And finally, (6) the use of AAS appears to confer an increased risk of life-threatening arrhythmia leading to sudden death, although the underlying mechanisms are still far from being elucidated. Taken together, various lines of evidence involving a variety of pathophysiologic mechanisms suggest an increased risk for cardiovascular disease in users of anabolic androgenic steroids.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20020375     DOI: 10.1007/978-3-540-79088-4_18

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  34 in total

1.  The Effect of Chronic Anabolic-Androgenic Steroid Use on Tp-E Interval, Tp-E/Qt Ratio, and Tp-E/Qtc Ratio in Male Bodybuilders.

Authors:  Elnur Alizade; Anıl Avcı; Serdar Fidan; Mustafa Tabakçı; Mustafa Bulut; Regayip Zehir; Zeki Simsek; Mert Evlice; Uğur Arslantaş; Hakan Çakır; Mehmet Yunus Emiroglu; Mustafa Akçakoyun
Journal:  Ann Noninvasive Electrocardiol       Date:  2015-01-28       Impact factor: 1.468

2.  National Athletic Trainers' Association position statement: anabolic-androgenic steroids.

Authors:  Robert D Kersey; Diane L Elliot; Linn Goldberg; Gen Kanayama; James E Leone; Mike Pavlovich; Harrison G Pope
Journal:  J Athl Train       Date:  2012 Sep-Oct       Impact factor: 2.860

Review 3.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

4.  [Cardiovascular alterations associated with doping].

Authors:  D Thieme; A Büttner
Journal:  Herz       Date:  2015-05       Impact factor: 1.443

5.  Long-term anabolic steroids in male bodybuilders induce cardiovascular structural and autonomic abnormalities.

Authors:  Octávio Barbosa Neto; Gustavo Ribeiro da Mota; Carla Cristina De Sordi; Elisabete Aparecida M R Resende; Luiz Antônio P R Resende; Marco Antônio Vieira da Silva; Moacir Marocolo; Rafael Silva Côrtes; Lucas Felipe de Oliveira; Valdo José Dias da Silva
Journal:  Clin Auton Res       Date:  2017-10-10       Impact factor: 4.435

6.  White matter abnormalities in long-term anabolic-androgenic steroid users: A pilot study.

Authors:  Johanna Seitz; Amanda E Lyall; Gen Kanayama; Nikos Makris; James I Hudson; Marek Kubicki; Harrison G Pope; Marc J Kaufman
Journal:  Psychiatry Res Neuroimaging       Date:  2016-12-10       Impact factor: 2.376

7.  Acute myocardial infarction in a young male wrestler: A case report.

Authors:  Hoorak Poorzand; Reza Jafarzadeh Esfehani; Peyman Hosseinzadeh; Mohammad Vojdanparast
Journal:  ARYA Atheroscler       Date:  2015-11

Review 8.  Illicit use of androgens and other hormones: recent advances.

Authors:  Gen Kanayama; Harrison G Pope
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-06       Impact factor: 3.243

9.  Subchronic nandrolone administration reduces cardiac oxidative markers during restraint stress by modulating protein expression patterns.

Authors:  Barbara Pergolizzi; Vitina Carriero; Giuliana Abbadessa; Claudia Penna; Paola Berchialla; Silvia De Francia; Enrico Bracco; Silvia Racca
Journal:  Mol Cell Biochem       Date:  2017-04-21       Impact factor: 3.396

10.  Global gene expression of fission yeast in response to cisplatin.

Authors:  L Gatti; D Chen; G L Beretta; G Rustici; N Carenini; E Corna; D Colangelo; F Zunino; J Bähler; P Perego
Journal:  Cell Mol Life Sci       Date:  2004-09       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.